arrow_back Trending Legislation
Share share

Enhanced Safety for Cell and Tissue Transplants: New Rules and Penalties.

This Act aims to improve the safety of human cell and tissue transplants by launching a national education campaign for patients and doctors about potential risks, including infection transmission. It also introduces significant financial penalties for companies that violate safety regulations regarding these products. Citizens will benefit from better information and increased confidence in the quality and safety of medical procedures.
Key points
Mandatory national campaign to educate the public and healthcare providers on the risks and benefits of human cell and tissue transplants.
Imposition of high civil penalties (up to $10 million) for establishments violating safety rules for cell and tissue products.
Requirement for the FDA to review and update guidelines for screening cell and tissue donors to enhance product safety.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Shandra Eisenga Human Cell and Tissue Product Safety Act
Print number: S 3733
Sponsor: Sen. Peters, Gary C. [D-MI]
Process start date: 2024-02-05
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Enhanced Safety for Cell and Tissue Transplants: New Rules and Penalties.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 3733.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-02-05.

What are the main provisions?

Key points include:

  • Mandatory national campaign to educate the public and healthcare providers on the risks and benefits of human cell and tissue transplants.
  • Imposition of high civil penalties (up to $10 million) for establishments violating safety rules for cell and tissue products.
  • Requirement for the FDA to review and update guidelines for screening cell and tissue donors to enhance product safety.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Peters, Gary C. [D-MI].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Analysis and Potential Impact of S 3733

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health